Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | PDE5A | O76074 | 5/20 | 0.43 |
| ▸ | PDE4A | P27815 | 4/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73787 | 0.89 | CYP2C9 (0.41) | CYP2C9CYP2C19CYP1A2PDE5APDE4A | |
| SCHEMBL27527897 | 0.81 | GRM5 (0.44) | GRM5CYP2C9CYP2C19CYP1A2PDE5A | |
| SCHEMBL27493710 | 0.81 | GRM5 (0.44) | GRM5CYP2C9CYP2C19CYP1A2PDE5A | |
| SCHEMBL13392157 | 0.80 | LMNA (0.40) | CYP2C9CYP2C19CYP19A1CYP2D6CYP3A4 | |
| SCHEMBL14971192 | 0.79 | CYP2C9 (0.47) | CYP2C9CYP2C19CYP1A2PDE5APDE4A | |
| SCHEMBL26464931 | 0.78 | ALOX5 (0.47) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL30967514 | 0.77 | PDE5A (0.44) | GRM5CYP2C9CYP2C19CYP1A2PDE5A | |
| SCHEMBL9490121 | 0.77 | LMNA (0.48) | CYP2C9CYP2C19CYP1A2PDE5APDE4A | |
| SCHEMBL9118185 | 0.77 | LMNA (0.48) | CYP2C9CYP2C19CYP1A2PDE5APDE4A | |
| SCHEMBL23717535 | 0.77 | GRM5 (0.46) | GRM5PDE5AL3MBTL1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | OCERA THERAPEUTICS, INC. | 2018-04-26 | — | — | US | disclosed |
| US-9493505-B2 | Macrocyclic modulators of the ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | OCERA THERAPEUTICS LLC | 2016-08-04 | — | — | US | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150148290-A1 | Macrocyclic Modulators of the Ghrelin Receptor | MALLINCKRODT LLC | 2015-05-28 | — | — | US | disclosed |
| US-8921521-B2 | Macrocyclic modulators of the Ghrelin receptor | OCERA THERAPEUTICS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20130211045-A1 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. (CA) | 2013-08-15 | — | — | US | disclosed |
| US-8497242-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2013-07-30 | — | — | US | disclosed |
| US-8450268-B2 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| US-RE42013-E1 | Macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. (CA) | 2010-12-28 | — | — | US | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | TRANZYME PHARMA INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | TRANZYME PHARMA INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| US-7491695-B2 | Therapy for endocrime disorders; gastrointestinal disorders; cardiovascular disorders; obesity; central nervous system disorders; antiproliferative agents ; using growth hormone secretagogue receptor | TRANZYME PHARMA INC. (CA) | 2009-02-17 | — | — | US | disclosed |
| US-7476653-B2 | Using growth hormone secretagague receptors; endocrime disorders; gastrointestinal disorders; cardiovascular disorders; central nervous system disorders; antiproliferative agents; antiinflammatory agents | TRANZYME PHARMA, INC. (CA) | 2009-01-13 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | GRM5 374/4885CYP2C9 1913/4885CYP2C19 1515/4885 |
| US-20180110824-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GRM5 135/4885CYP2C9 3205/4885CYP2C19 2470/4885 |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | GRM5 504/4885CYP2C9 1496/4885CYP2C19 1154/4885 |
| US-20150148290-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GRM5 135/4885CYP2C9 3205/4885CYP2C19 2470/4885 |
| US-20090221689-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GRM5 135/4885CYP2C9 3205/4885CYP2C19 2470/4885 |
| US-20090170757-A1 | METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GHRHR, GIPR | GRM5 113/4885CYP2C9 3321/4885CYP2C19 2517/4885 |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | GRM5 374/4885CYP2C9 1913/4885CYP2C19 1515/4885 |
| US-20130211045-A1 | MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR | GHSR, GIPR, GHRHR | GRM5 135/4885CYP2C9 3205/4885CYP2C19 2470/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | GRM5 386/4885CYP2C9 1852/4885CYP2C19 1458/4885 |
| US-20090198050-A1 | Macrocyclic Modulators of the Ghrelin Receptor | GHSR, GIPR, GHRHR | GRM5 135/4885CYP2C9 3205/4885CYP2C19 2470/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | GRM5 113/4885CYP2C9 3321/4885CYP2C19 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.